FDA Panel Supports Continued Testing of Pain Drugs
WASHINGTON (AP) - A panel of arthritis experts has recommended that the federal government allow continued testing of an experimental class of pain drugs for arthritis, despite links to bone decay and joint failure.
The Food and Drug Administration's 21-member panel of arthritis experts voted unanimously that research on the nerve-blocking drugs should continue, with certain safety precautions to protect patients. Reports of joint failure led the agency to halt studies of the drugs in 2010.
Pfizer, Johnson & Johnson and Regeneron Pharmaceuticals have asked the FDA to lift the moratorium on testing of their drugs.
"There's clearly a worrisome safety signal, but in spite of that I think there's an unmet need in certain patient populations," said panelist Dr. Sherine Gabriel, of the Mayo Medical School of Rochester of Minnesota.
- FDA Review Favors First Drug for HIV Prevention
- Pain Drugs
- FDA Approves "Plan B" for OTC Sale to Women Ages 15 and Up
- New FDA Approved Silicone Breast Implants
- Georgia to Require Drug Tests for Welfare Benefits
- New Drug Suppliers to Ease Two Cancer Drug Shortages
- Drug Testing
- Revised Drug Testing Bill
- Drug Testing State Employees
- Random Drug-Testing Bill Dies in State House